Brain-CA Technologies Secures Patents for Innovative AI based on Cellular Automata
Brain-CA Technologies has secured patents for a new AI solution based on Cellular Automata that will revolutionize the AI industry. ...
Brain
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14,...
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer’s diseaseROCHESTER,...
Zeto Among America’s Fastest-Growing Private Companies on the 2024 Inc. 5000 List
NEW YORK, Aug. 13, 2024 /PRNewswire/ -- Inc. revealed today that Zeto, Inc. ranks No. 1311 on the 2024 Inc....
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
The ISO 13485 certification is a validation of the Company’s robust quality systemBRAINTREE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) --...
Notice of Nexstim Plc’s Half-Year Report H1 2024
Press release, Helsinki, 13 August 2024 at 3 PM (EEST) Notice of Nexstim Plc’s Half-Year Report H1 2024 Nexstim Plc...
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and executionExpanded...
New Scientific Article on NeuroRestore ACD856 and its Improved Cognition and Disease Modification of Alzheimer’s Disease
STOCKHOLM, SE / ACCESSWIRE / August 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
Masimo W1® Medical Watch Receives FDA 510(k) Clearance for Connectivity to the Masimo SafetyNet® Telemonitoring System
Secure Bluetooth® Connectivity Allows Continuous, Accurate Wrist-based Measurements to be Seamlessly Relayed to Caregivers via the Masimo Secure Health Data...
Orphan Drugs and Rare Diseases Conference (Boston, MA, United States – October 17-18, 2024) – Navigating Orphan Drugs & Rare Diseases from Regulation to Detection & Precision Treatments – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs and Rare Diseases Conference" has been added to ResearchAndMarkets.com's offering. The 2 day Orphan Drugs and...
MIRA Pharmaceuticals Unveils Ketamir-2’s Principal Metabolite: Nor-Ketamir – a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
This breakthrough in bioavailability and formulation showcases the potential for advanced, at home neurological treatments.MIAMI, FL / ACCESSWIRE / August...
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to...
WVU Medicine To Host Brain-Machine Interface (BMI) Summit Charting the Future of Neurotechnology
Leading Neuroscientists, Technologists, Regulators, and Venture Capitalists Convening in West Virginia MORGANTOWN, W.Va., Aug. 9, 2024 /PRNewswire/ -- West Virginia...
Genova Diagnostics Partners with Neurocode to Launch Innovative Alzheimer’s Assessment
ASHEVILLE, N.C., Aug. 9, 2024 /PRNewswire/ -- Genova Diagnostics, a global leader in clinical laboratory services, proudly announces the launch of...
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month – Created by a World-Class Pharmaceutical Research & Development Team
TORONTO, ON / ACCESSWIRE / August 9, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update on its...
Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - August 9, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or...
WorkFar Robotics Unleashes Sentient Humanoid Robots “Syntro” into the WorkForce
WorkFar Robotics' sentient humanoid "Syntro" is a sophisticated, AI-enhanced robot in human form that can be effortlessly controlled by a...
MEDFAR, Fastest-growing EMR/EHR Provider, Announces Successful Entry Into the U.S. Primary Care Market with COMTRON Integration
MEDFAR Unveils New Brand Identity Reflecting Its Growth and Ambitious Healthcare Goals MONTREAL, Aug. 8, 2024 /PRNewswire/ - MEDFAR, developer...
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globallySARASOTA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE)...